

CURRICULUM VITAE
Michael V. Drake, M.D.

EMPLOYMENT HISTORY:

President, The Ohio State University	2014-present
Chancellor, University of California, Irvine Distinguished Professor Ophthalmology and Education	2005-2014
Vice President for Health Affairs, University of California Systemwide	2000-2005
Steven P. Shearing Professor of Ophthalmology, UCSF	1998-2005
Vice Chair, Department of Ophthalmology, UCSF	1998-2000
Senior Associate Dean for Admissions and Extramural Academic Programs, UCSF School of Medicine	1998-2000
Interim Associate Dean for Student Affairs	1997-1998
Professor of Ophthalmology; Associate Dean for Admissions and Student Programs, UCSF	1993-1998
Chief, Vision Care and Research Unit, Beckman Vision Center, UCSF	1991-1993
Assistant Dean, Student Affairs, UCSF	1991-1993
Associate Professor of Ophthalmology, UCSF	1987-1993
Chief, University Eye Clinic, UCSF	1979-1991
Assistant Professor of Ophthalmology, UCSF	1979-1987

EDUCATION:

Harvard Business School Advanced Management Program (AMP 167)	2005
University of California, San Francisco	MD 1975
Stanford University	AB 1974
Sacramento City College	1967-1969

POST-GRADUATE TRAINING:

Massachusetts Eye & Ear Infirmary, Harvard Medical School (Glaucoma)	Sep-Dec 1981
Fellowship: UCSF	1979-1981
Residency: UCSF	1976-1979
Internship: Martin Luther King, Jr. General Hospital, Los Angeles	1975-1976

BOARD CERTIFICATIONS:

American Board of Ophthalmology	1981
National Board of Medical Examiners	1976

DIRECTORSHIPS (CURRENT)

AMERICAN TALENT INITIATIVE

Member, Steering Committee 2015-present

ASSOCIATION OF AMERICAN UNIVERSITIES

Member, Board of Directors 2013-2020

Chair, Membership Committee 2016-2017; 2018-2020

Member, Review Committee 2016-2019

Member, Audit and Finance Committee 2016-2018

Member, Membership Committee 2012-present

Chair, Board of Directors October 2017-October 2018

Past Chair, Board of Directors October 2018-October 2019

ASSOCIATION OF PUBLIC AND LAND-GRANT UNIVERSITIES

Member, Board of Directors 2010-2011

Member, Board of Directors 2014-present

Secretary, Council of Presidents 2014-2015

Chair, Council of Presidents 2015-2017

Chair-Elect, Board of Directors 2017-2018

Chair, Board of Directors 2018-2019

Past Chair, Board of Directors 2019-2020

Chairman, Commission on Access, Diversity and Excellence 2011-2012

BANK OF THE WEST

Member, Board of Directors 2010-present

Member, Executive Committee 2010-present

Member, Compensation Committee (Chair 2018-present)

Member, Nominating Committee (Chair 2018-present) 2011-present

Member, Trust Committee (Chair 2016-2018) 2012-2018

BANCWEST

Member, Board of Directors 2010-March 2016 (legacy BWE)

Member, Board of Directors March 2016-2019 (new BWE)

Member, Risk Committee 2015-March 2016 (legacy BWE)

Member, Risk Committee March 2016-2019 (new BWE)

BIG 10 ATHLETIC CONFERENCE

Member, Council of Presidents/Chancellors 2014-2018

Member, Executive Committee 2016-present

Vice Chair, Council of Presidents/Chancellors 2018-present

BNP PARIBAS USA, INC.

Member, Audit Committee July 1, 2016-present

Member, Compensation Committee July 1, 2016-present

THE COMMONWEALTH FUND

Chair, Board of Directors 2019-present

Member, Board of Directors 2008-present

Member, Governance & Nominating Committee (Chair 2017-2019) 2008-present

NATIONAL COLLEGIATE ATHLETIC ASSOCIATION

Chair, Board of Governors May 2019-present

Member, Board of Directors; Executive Committee; Governance Committee. 2012-2014

Member, Board of Governors Commission to Combat Campus Sexual Violence 2016-2018

Chair, Board of Governors Ad Hoc Committee to Promote Cultural Diversity & Equity 2016-2017

Member, Division I Presidential Forum 2015-2018

Member, Division I Sport Organizational Structure Working Group 2015-2018

ROCK AND ROLL HALL OF FAME AND MUSEUM
 Member, Board of Directors 2015-present

UNIVERSITY INNOVATION ALLIANCE
 Member, Executive Board 2014-present

DIRECTORSHIPS (RECENT)

ALPHA OMEGA ALPHA Honor Medical Society
 Member, Board of Trustees 1996-2008
 President 2002-2005

ASSOCIATION OF ACADEMIC HEALTH CENTERS (AAHC)
 Member, Board of Trustees 2002-2008
 Chair 2007-2008
 Executive Committee Member 2006-2008

BIG WEST ATHLETIC CONFERENCE
 Member, Board of Directors 2005-June 2014
 Chair 2009-2011
 Vice Chair 2007-2009

CALIFORNIA HEALTHCARE FOUNDATION
 Member, Board of Directors 2010-March 2015

CALIFORNIA HEALTHCARE INSTITUTE
 Member, Board of Directors 2006-June 2014

GILEAD SCIENCES, INC
 Member, Health Policy Advisory Board 2008-February 2016

ORANGE COUNTY PERFORMING ARTS CENTER
 Member, Board of Trustees 2008-2010

TIGER WOODS LEARNING CENTER
 Member, Board of Directors 2009-2011

PROFESSIONAL ASSOCIATION ACTIVITIES

ASSOCIATION OF AMERICAN UNIVERSITIES
 Panelist, A Conversation with AAU Presidents and Chancellors January 2018

ASSOCIATION OF PUBLIC AND LAND GRANT UNIVERSITIES
 Panelist, “The Age of Disruption: Navigating, Innovating, and Excelling” November 2017

AMERICAN TECHNOLOGY COUNCIL
 Higher education representative June 2017

ARCHIVES OF OPHTHALMOLOGY
 Member, Editorial Advisory Board 2007-2012

WESTERN ASSOCIATION OF SCHOOLS AND COLLEGES
 Chair, Capacity and Preparatory Review, Scripps Research Institute March 2009

AMERICAN ASSOCIATION OF MEDICAL COLLEGES (AAMC):
 AAMC NIH Special Action Committee
 Title VII Review Committee January 2004

Medical Student Admissions after Affirmative Action April 2001
 Western Regional Meeting April 1999

SP-1, Prop. 209, and Medical School Admissions (presentation),
 Western Regional Meeting: Student Advice (panelist) April 1998

Address to Dean’s Assistants Group,
Cultural Competency in the Academic Medical Center November 1997

Panelist: Diversity and Admissions After Affirmative Action November 1997

Discussant: Medical School Admissions Workshop	
Western Regional AAMC Meeting	April 1997
Keynote Address: Minority Affairs Selection Meeting/Workshop, San Diego, CA	February 1996
Panelist: <i>Professionalism in Medical Education</i> , Western Regional GSA/MAS Meeting	April 1996
Panelist: <i>Medical Education in the 21st Century: Who do we train? What do we teach?</i>	November 1995
Panelist: Medical Student Advising, AAMC Western Regional Conference	April 1994
UCSF Graduate Student Affairs/Minority Affairs Representative	1984-1987
Facilitator: <i>Diversity, At What Price?</i>	1991-2000
AAMC Student Representatives Meeting, Western Regional Conference	April 1994
INSTITUTE OF MEDICINE	
Committee on Institutional and Policy-Level Strategies for Increasing the Racial and Ethnic Diversity of the U.S. Healthcare Workforce	2002-2003
WESTERN JOURNAL OF MEDICINE	
Member, Editorial Advisory Board	2000-2002
ALPHA OMEGA ALPHA (UCSF)	
Councilor, Alpha Chapter	1993-2000
AMERICAN MEDICAL ASSOCIATION:	
AAMC/AMA-LCME Faculty Fellow	1998
Site visit: Meharry Medical College	
NATIONAL ASSOCIATION OF MEDICAL MINORITY EDUCATORS	
Medical Educators Conference, Keynote Address: <i>Medical School Admissions in the 1990s</i>	March 1998
AMERICAN ACADEMY OF OPHTHALMOLOGY	
American Academy of Ophthalmology Public Information Committee	1997-1998
American Academy of Ophthalmology Summer Institute, Glaucoma Section	July 1992
Task Force on Educational Technology (Course Director)	1991-1992
AMERICAN BOARD OF OPHTHALMOLOGY	
Associate Examiner	1984-1994
INTERNATIONAL PERIMETRIC SOCIETY	
Educational Standards Committee	1991-1993
NATIONAL MEDICAL ASSOCIATION	
Course Director, Pre-convention Symposium	1992
NATIONAL EYE INSTITUTE	
Special Projects Grant Review Committee	1990, 1991

Reviewer: *American Journal of Ophthalmology, Archives of Ophthalmology, Survey of Ophthalmology, Investigative Ophthalmology and Visual Science, JAMA, Ophthalmology, Glaucoma, Western Journal of Medicine, Saudi Arabian Journal of Ophthalmology, Journal of the National Medical Association*

HONORS & AWARDS

APLU CGA Exemplary University President in Government Relations Award	May 2020
OSU Annual Staff Achievement Award Designated as “Dr. Michael V. Drake President’s Award”	2020
Champions of Health National Medical Fellowships Academic Excellence Award	2019
Doctor of Humane Letters, <i>Honoris Causa</i> , Princeton University	2019
University of California-Irvine Medal	2017
10th Annual King Arts Legends & Legacies Award	2017
University of California Presidential Medal	2014
Doctor of Humane Letters, <i>Honoris Causa</i> , Charles R. Drew University	2012
Orange County Human Relations Commission, Commendation	2010
Multicultural Alumni Hall of Fame, Stanford University	2008
Health Initiative of the Americas, Bi-national Health Pioneer Award	2008
Orange County Human Relations Commission, Commendation	2008

Foundation Fighting Blindness Visionary Award	2008
The California Wellness Foundation, Champions of Health Professions Diversity Award	2007
American Academy of Arts & Sciences, Election	2007
Frederick M. Roberts Award, California Legislative Black Caucus Foundation	2007
UCSF School of Medicine, White Coat Ceremony Keynote.	2004
Herbert M. Nickens Award, AAMC	2004
UCSF Gold Headed Cane Society, Speaker's Cane	2003
UCSF School of Medicine Alumnus of the Year	2000
S. J. Kimura Teaching Award UCSF Dept. of Ophthalmology	1999
Institute of Medicine, National Academy of Sciences, Election	1998
UCSF School of Medicine White Coat Ceremony, Physicians Oath	1998
Mentor Award, UCSF/Black Students Health Alliance	1997
UCSF White Coat Ceremony, Address	1997
Clinical Teaching Award (At graduation, UCSF Class of 1995)	1995
Honor Award, American Academy of Ophthalmology	1993
Portrait Unveiling (Remarks, Unveiling), Chancellor's Retirement	1993
Nominee, Outstanding Lecture (Class of 1994 UCSF)	1992
Selected by Senior Class to Lead Physician's Oath, UCSF School of Medicine	1991
Martin Luther King, Jr., Award for University Service	1991
Nominee, Outstanding Lecture (Class of 1993 UCSF)	1991
Outstanding Service Award, Black Students' Health Alliance (BSHA)	1990
Distinguished Employee Citation, Chancellor's Office (125 th Anniversary Celebration)	1990
Nominee, Outstanding Lecture, (Class of 1992 UCSF)	1988
Sigma Pi Phi Honorary Fraternity	1988
Distinguished Alumnus Award, AOA Students (Class of 1989)	1988
Outstanding Service Award, John Hale Medical Association	1988
Outstanding Service Award, Dean's Office UCSF	1988
Michael J. Hogan Award (laboratory research)	1980
Asbury Award (clinical research)	1978
Chancellor's Award for Public Service	1974
President's Undergraduate Research Fellowship (Systemwide)	1974

PUBLIC SERVICE (CALIFORNIA)

Member, The California Endowment Task Force for Health Care Options in S. Los Angeles	2008-2009
Fellow, California Council on Science and Technology	2006-2008
California Health Benefit Review Program (AB 1996 implementation)	2002-2005
ACR 139 Implementation Committee, Chair	2003-2005
Member California Healthcare Workforce Commission	2002-2005
Member, California/México Commission on Science and Technology	2002-2005
Member, Steering Committee on the Future of King/Drew Medical Center	2004
King/Drew Medical Center, Chair	
Co-Chair Committee on The Protection of the Public Health (SSCOT)	2001-2003

SERVICE (UC SYSTEM)

WASC Reaccreditation, UC Merced	2017
Co-Chair: UC Commission on the Future Access & Affordability Workgroup	2009-2014
Advisory Board Member: Migration and Health Research Center	2009-2014
Member, UC School of Global Health Board of Directors	2009-2014
University of California Commission on the Future	2009-2011
Ex-Officio Member and UC Irvine Calit2 Representative: President's Board on Science and Innovation	2005-2010

Member, UC School of Global Health Ad Hoc Planning Group	2008-2009
Co-Chair: California/México Health Initiative	2002-2005
California State Summer School for Mathematics and Science (COSMOS) Advisory Board Member	2000-2005
Blue Ribbon Panel on Health Sciences Education, UC Riverside	January 2004
UC Merced Planning Task Force, UCSF Representative	1998- 2000
Medical School Admissions/Diversity Task Force	1999-2000
UCLA PREP program, Keynote Address, Finishing Exercise	August 1999
UC Graduate and Professional Admissions and Outreach Programs	April 1999
University-Wide Coordinating Committee for Graduate and Professional School Admissions	1995-1997
Report to UC Regents: Medical School Admissions	November 1994
University-Wide Task Force on Campus Community	1991-1992
Academic Senate Student Affirmative Action Committee, Chairman	1989-1991
Academic Senate Student Affirmative Action Committee, Committee Member	1987-1991

COMMENCEMENT ADDRESSES

Morgan State University (scheduled 2020, postponed due to COVID-19)	pending
Columbus State College	2015
Charles R. Drew University	2012
Saddleback College	2011
Washington University, St. Louis, School of Medicine	2009
UCSF School of Nursing	2008
UC Berkeley School of Optometry	2003
UCSF School of Medicine	2001
UCLA School of Dentistry	2001
UCSF School of Medicine	1999
UCSF School of Medicine	1993

LEGISLATIVE TESTIMONY

House Finance Committee on Higher Education	March 2017
House Finance Committee on Higher Education	February 2015
California Senate Hearing on Admissions re: eligibility requirements for UC	April 2009
United States House of Representatives, Financial Services Committee (Frank) re: The Role of Public Investment in Promoting Economic Growth	March 2007
California Senate Health Committee Informational Hearing re: UC Irvine Medical Programs: Diagnosis and Prescription for Accountability	May 2006
California Assembly Budget Subcommittee 2, Education Finance (Dymally)	May 2005
California Senate Hearing on UC Admissions (Ortiz)	February 2005
California Senate Hearing re: Department of Corrections (Romero)	September 2004
Governor’s Hearing on California Performance Review, Long Beach CA	September 2004
California State Senate Select Committee on College & University Admissions and Outreach	January 2004
California Assembly Select Committee, re: King-Drew Medical Center	January 2004
United States Senate, (Judiciary) Subcommittee on Technology, Terrorism and Government Information (Feinstein)	November 2001
California Assembly: UC Medical School Admissions	September 1997
California Assembly: UC Medical School Admissions	March 1997
(> 200 additional legislative and agency visits, Sacramento and Washington, D.C.)	1995-present

UCSF School of Medicine

Student Family Network Advisor	1993-2002
--------------------------------	-----------

Essential Core Curriculum Revision Committee	2000
Search Committee, Director, Academy of Medical Educators	2000
Chancellor' Executive Committee on Diversity	1999-2000
UCSF Policy Board on Student Outreach, Recruitment, Retention, and Academic Enrichment	1997-2000
Director, UCSF School of Medicine Advising Surgery and Surgical Specialties	
Career Advisor, Ophthalmology	1991-1994
Student Advisor, School of Medicine	1985-2000
Faculty-Student Liaison Committee	1988-2000
Faculty Councilor, Alpha Omega Alpha Honor Medical Society, UCSF chapter	1991-2000
Faculty Student Committee on Minority Recruitment and Retention, Chair, Steering Committee, Medical Scholars Program	1985-2000
Member, Group on Student Affairs, AAMC	1985-2000
Editor, Alumni/Faculty Bulletin	1988-1990
Council	1985-2000
Executive Committee, Editorial Committee	1988-2000
Residency Selection Committee, Ophthalmology	1979-1996
Chair	1982-1983
Medical Education/Clinical Objectives Committee	1999
Search Committee (Chair): UCSF/Fresno Associate Dean	1998-99
UCSF Career Day (high school students)	1985-1988
UCSF Course Directors and Curriculum Committee Retreat	1991, 1993-1999
Welcoming Orientation Address, Entering Freshmen Class UCSF School of Medicine	1985-1999
UCSF Campus Planning Task Force	1997-98
Search Committee: UCSF Associate Dean, Student Affairs	1997
Search Committee: UCSF Associate Dean, Curricular Affairs	1997
Association of UCSF Clinical Faculty Meeting Address: <i>Admissions After 209 and SP-1</i>	October 1997
UCSF Faculty Leadership Retreat, Section Leader	January 1994
Search Committee: (Advisory) UCSF/UCB Joint Medical Program Director	Nov-Feb 1993-94
Search Committee: UCSF Sr. Vice Chancellor/Academic Affairs	1993
Search Committee: UCSF VA Associate Chief/Education	1993
Ambulatory Care Committee	1979-1993
UCSF Faculty Leadership Retreat Address / Panel Moderator	January 1993
Planning Committee, 1993 School of Medicine Faculty Leadership Retreat	1992-1993
Search Committee, Dean, Graduate Division & Vice Chancellor of Student Services	1992
Planning Comm. UCSF School of Medicine Family Weekend Address: <i>The Medical School Experience</i>	October 1992
Association of UCSF Clinical Faculty Meeting Address: <i>Medical Education in the 90s</i>	November 1992
UCSF Department of Dermatology Faculty Retreat Address: <i>Successful Strategies for Achieving Housestaff Diversity</i>	November 1992
Panelist, Research Opportunities for Underrepresented Minority Medical Students	September 1992
Chancellor's Special Review Committee on Campus Administrative Services	August 1992
Alumni/Faculty Association	1983-1992
President	1990-1991
Pathway Advisor, School of Medicine	1985-1991
Standing Screening Committee, Class of 1990	1987-1990
Executive Committee UCSF School of Medicine	
Facilitator, Faculty Student Support Group	1988-1990

Jesse C. Davis Memorial Scholarship Fundraiser, Planning Committee Chair	1988
Admissions Committee, School of Medicine	1979-1987
Chair Panel III, Member Executive Council	1982-1987
UCSF Faculty Retreat Address: <i>Historical perspectives and current philosophy concerning minority admissions to UCSF School of Medicine</i>	1986
Affirmative Action Day	1985
UCSF Career Day (University students)	1985
Search Committee: Nursing Director, Ambulatory Surgery Center	1985
Affirmative Action Day Committee, Co-Chair	1985
Search Committee: LPPI / Department of Psychiatry Chair	1984-1985
Panelist, Recruitment & Retention Symposium, School of Medicine representative	1985
Health Policy Group on Medical Education in the Ambulatory Environment	1985
Ambulatory Surgery Committee	1983-1985

RECRUITING FOR SCHOOLS OF MEDICINE:

UCSF Minority Students Weekend	1986-2002
UC Berkeley	1993, 1994-2002
Stanford University	1986, 1987, 1989, 1993-2001
UC Santa Barbara	1996, 1997, 2000
San Diego State	1999
Harvard University	1985, 1986, 1990, 1998
UCLA	1986, 1995(x2), 1998
Xavier University	1986, 1989, 1998
Atlanta University	1990
University of Southern California	1984, 1986
San Francisco State University	1984, 1986
Howard University	1985
Johns Hopkins	1985

OTHER (partial list):

American Technology Council, Advisory Board, Golden Gate Bank	1988-1992
Free Medical Clinic Black Chemical Dependency Program	1988-1990
Advisory Board, Glide Memorial Church/Haight Ashbury	1988

MEMBERSHIPS (current)

Alpha Omega Alpha
 American Academy of Arts & Sciences
 American Academy of Ophthalmology
 Association of Academic Health Centers
 Blue Ridge Academic Health Group
 Chandler Grant Eye Society
 Frederick C. Cordes Eye Society
 Institute of Medicine, National Academies of Science
 National Medical Association
 Society of Medical Administrators

MEMBERSHIPS (previous active/leadership)

Alumni Faculty Association, UCSF
 Association for Research in Vision & Ophthalmology (ARVO)

John Hale Medical Association
 UCSF Foundation
 Western Glaucoma Study Club

INVITED PRESENTATIONS, academic symposia

(numbered by event rather than individually):

@200-500 remarks each year as Ohio State president	July 2014-present
210. UCI PRIME-Wide Conference	January 2020
209. Keynote: Investiture of Thomas Parham, CSUDH	February 2019
208. Keynote: 2018 C-Suite Awards: The Most Admired Executives in Central Ohio	September 2018
207. Stanford Grand Rounds	March 2018
206. Keynote: Research Universities Leading Place-Based Climate Action Initiative, 2018 Higher Education Leadership Summit	February 2018
205. Keynote: National Agricultural Alumni and Development Association	June 2017
204. Economic Club of Washington, D.C.: 2017 Higher Education Panel	April 2017
203. Sonoma State University Inauguration of Judy K. Sakaki	April 2017
202. Dean Lawrence B. Harkless Endowed Lecture: <i>Higher Education, Health Care and the Future of America</i>	March 2017
201. Columbus Metropolitan Club	September 2016
200. City Club of Cleveland: <i>21st-Century Ohio State: Re-envisioning Our Land-Grant Mission</i>	February 2016
199. Patterson Land-Grant Lecture	May 2015
198. National Conference on Campus Sexual Assault and Violence Keynote Presidents Panel	February 2015
197. Keynote: American Association of Physicians of Indian Origin of Central Ohio (AAPI) (@100-150 remarks each year as UCI Chancellor)	September 2014 2009-2014)
196. Cordes Society Annual Meeting Michael Hogan Lecture: <i>Social Determinants of Health</i>	March 2010
195. Glaucoma Research & Education Group 14 th Annual Glaucoma Symposium <i>Healthcare Reform: Perspectives and Solutions</i>	February 2010
194. UC Merced Academic Innovation Symposium	November 2009
193. Ernest K Goodner Memorial Lecture UCSF: <i>Envisioning Global Health</i>	October 2008
192. Glaucoma Research & Education Group 12 th Annual Glaucoma Symposium	February 2008
191. Glaucoma Research & Education Group, 11 th Annual Glaucoma Symposium	February 2007
190. National Medical Association, Roger Mason Lecture	August 2006
189. Glaucoma Research & Education Group 9 th Annual Glaucoma Symposium	February 2005
188. AHC Symposium on Safety Net Hospitals (moderator)	July 2004
187. Lighting the Path Symposium, Texas Tech University <i>In the Nation's Compelling Interest</i>	April 2004
186. Glaucoma Research & Education Group, San Francisco <i>Glaucoma, System Failures, and Society</i>	February 2004
185. Binational Forum on Migrant Policy, UC Los Angeles Address: <i>Differences, Disparities, and Discrimination</i>	October 2003
184. UCSF Ophthalmology Grand Rounds	September 2003
183. National Conference of State Legislatures Presentation: <i>The California Health Benefits Review Program</i>	July 2003
182. William Kerr Lecture, UCSF Gold Headed Cane Society	May 2003
181. California Schools of Medicine Premedical Advising Conference, UC Davis Keynote Address	March 2003
180. Foundation for Glaucoma Research Symposium Corneal Pachymetry and Glaucoma, San Francisco	February 2003
179. Charles R. Drew School of Science and Medicine, Los Angeles	

- Presidential Symposium: *The Future of Medical Education* January 2003
178. American Academy of Ophthalmology, Orlando October 2002
 Challenge the Experts: *Case Presentations in Glaucoma Management*
 Skills Transfer Course: *Combined Cataract and Glaucoma Surgery*
177. Consortium of 13 Annual Meeting, Stanford University, November 2002
 Address: *Diversity and Excellence in Medical Education: Admissions Policies and Procedures*
176. Ernest K Goodner Memorial Lecture UCSF: September 2002
Assessing and Treating Early Glaucoma
175. COSMOS Summer School Session, UC Davis July 2002
 Keynote Address: "*Why You Should Consider a Career in Health Sciences?*"
174. California Schools of Medicine Premedical Advising Conference, UC Berkeley February 2002
 Keynote Address
173. Foundation for Glaucoma Research Symposium, San Francisco, *The Ocular Hypertension Treatment Study, Preliminary Five-Year Results* February 2002
172. California Schools of Medicine Premedical Advising Conference, Los Angeles October 2001
 Keynote Address
171. Testimony before the U.S. Senate Subcommittee on Technology, Terrorism, and Government Information Hearing on Germs, Toxins and Domestic Terrorist Threats November 2001
170. UC San Diego Diversity Symposium May 2001
 Keynote Address: "*Achieving Diversity: Challenges to the Academic Community*"
169. UC Black Administrators Council; Keynote Address, Sacramento April 2001
168. Foundation for Glaucoma Research Symposium: "*Detecting and Following Patients With Early Glaucoma*" San Francisco February 2001
167. UC Management and Leadership Conference, San Diego December 2000
 Address: *The Future of Health Sciences Education*
166. UCSF Department of Medicine Grand Rounds: September 2000
The Future of Medical Education
165. Student National Medical Association Annual Meeting, Los Angeles April 2000
 Keynote speaker
164. Foundation for Glaucoma Research, SF Symposium: February 2000
 The Ocular Hypertension Treatment Study: *What Have We Learned?*
163. UCSF Ophthalmology Grand Rounds Lecture: January 2000
Medical Education: Revisited and Revised
162. University of Illinois, Chicago, Department of Medical Education 40th Anniversary Meeting Lecture Panel *Excellence through Diversity* July 1999
161. UC Black Administrators Council Lake Arrowhead March 1999
 Lecture: *Medical School Admissions after Prop. 209*
160. Glaucoma Research Foundation Annual Course, San Francisco February 1999
 Lecture: *Automated Perimetry Update: Making the Right Choice*
 Experts Panel
159. American Academy of Ophthalmology, Chicago Skills Transfer Course: November 1998
Interpreting Automated Perimetry
158. Visiting Professor, University of Rochester May 1998
 Lectures: *Evidence Based Ophthalmology; Automated Perimetry*
157. Chicanos in Health Education, California State Conference April 1998 Keynote Address: *The Value of a Medical Education*
156. Glaucoma Research Foundation, San Francisco February 1998 Annual course lecture: *Evidence Based Ophthalmology*
155. Grand Rounds, Department of Ophthalmology, UCSF 1997 (x2), 1998
154. Visiting Professor, Stanford University February 1998

153. American Academy of Ophthalmology, San Francisco November 1997
Lecture: *Rational Use of Visual Field Testing Combined Trabecular and Cataract Surgery*
Course: *Visual Field Interpretation*
152. Glaucoma Research Foundation February 1997
151. Orbis International Post Graduate Course; Bangalore, India February 1996
Lecture: *Ultrasonic Biomicroscopy in Pigmentary Glaucoma*
Lecture: *Automated Perimetry in Glaucoma*
Lecture: *Combined Trabeculectomy and Cataract Extraction*
Lecture: *Post Surgical Care of the Glaucoma Patient*
Lecture: *Diagnosis and Treatment of Ocular Hypertension*
Live Interactive Surgical Demonstration: Four Glaucoma Filtration Procedures,
Two Laser Peripheral Iridectomies
150. Grand Rounds, Mintu Eye Hospital February 1996
Lecture: *Treatment of Low Tension Glaucoma*
149. Association of Technical Personnel in Ophthalmology, San Francisco December 1995
Lecture: *The Ocular Hypertension Treatment Study*
148. American Academy of Ophthalmology; Atlanta November 1995
Course: *Small incision phacoemulsification and trabeculectomy*
American Association of Medical Colleges; Washington, D.C. October 1995
Lecture: *Physician Race, Ethnicity, and Practice Patterns*
Lecture: *Affirmative Action and the University of California*
146. Grand Rounds, UCSF, Dept. of Ophthalmology October 1995
Lecture: *UCSF Medical School Admissions: Past Practice and Future Trends*
145. ALTA Eye Society, Sacramento, CA October 1995
Lecture: *Modern Management of Normal Tension Glaucoma*
144. Grand Rounds, UCSF, Dept. of Ophthalmology Patient Section: September 1995
Myopia and Glaucomatous Visual Field Loss
143. Harvard Med School/Mass. Eye and Ear Infirmary July 1995
Basic Science Course ("Lancaster Course") at Colby College; Waterville, ME
Lecture: *Automated Perimetry*
Lecture: *Glaucomatous Optic Atrophy*
142. National Medical Association; Ophthalmology Section; Atlanta July 1995
Lecture: *Managing Low Tension Glaucoma*
141. Pacific Coast Oto-Ophthalmologic Society, Maui June 1995
Lecture: *Ocular HTN Treatment Study*
Lecture: *Low Tension Glaucoma*
Lecture: *Selecting Medical Students and Residents for the Future*
140. Ophthalmic Symposium; San Francisco, Lecture: June 1995
Managing Glaucoma Suspects
139. Grand Rounds, UCSF Dept. of Ophthalmology May 1995
138. Ophthalmic Symposium: Cairo, Egypt April 1995
Lecture: *Automated Perimetry*
Lecture: *Low Tension Glaucoma Diagnosis and Management;*
Lecture: *Small Incision Surgery*
137. Grand Rounds; King Khalid Eye Specialist Hospital, Riyadh, Saudi Arabia: April 1995
Automated Perimetry Using Short Wavelength Stimuli April 1995
136. Ophthalmic Symposium; Jeddah and Riyadh, Saudi Arabia
Lecture: *Combined Phaco-emulsification and trabeculectomy*
135. Saudi Arabian Glaucoma Society, Riyadh, Saudi Arabia (Guest of Honor) April 1995
Papers: *Visual Field and Optic Disc Changes in Normal Tension Glaucoma; The Use of Calcium Channel Blockers in Normal Tension Glaucoma; Treating Ocular Hypertension*

134. Satellite Panel Discussion (US - Saudi Arabia): April 1995
Modern Management of Low Tension Glaucoma
133. Jules Stein Symposium, UCLA April 1995
 Papers: *Calcium Channel Blockers in Normal Tension Glaucoma; Automated Perimetry Update: New Software and Short Wavelength Perimetry*
132. Medical Effectiveness Research Center, Monthly Conference March 1995
131. Grand Rounds, UCSF Department of Dermatology: March 1995
Selecting the Best Medical Students
130. Grand Rounds, Cal Pacific Medical Center, San Francisco January 1995
 Lecture: *Short Wavelength Photoreceptor Sensitivity in Early Glaucoma*
 Lecture: *The Ocular Hypertension Treatment Study*

Lectures 1-129 1979-1994

GRANTS (recent)

Grants at UC-Irvine (as principal investigator)

UCSF Professorship Grants

HRSA/Hispanic Center of Excellence	\$1,698,000	PI	2001-2006
HPPI for UCSF Fresno Latino Center	\$349,982	PI	2002-2005
California Endowment, Planning & Initial Funding, PRIME-LC	\$650,000	PI	2004
California Wellness Foundation	\$250,000	PI	2002-2004
California Endowment, Diversity in Medical Education	\$4,280,000	PI	2001-2004
NEI: Ocular Hypertension Treatment Study	\$423,000	PI	1999-2004
California Alliance for Minority Participation	\$125,000	PI	
NEI: Ocular Hypertension Treatment Study	\$2,470,000	PI	1994-2006
Legislative Post Baccalaureate Recruitment 5%	\$112,500	PI	1999

GRANTS (previous)

NIH MEDTEP [MERC] (10% effort, investigator)	\$3,750,000	(direct)	1993-1998
That Man May See, Inc. HFA for OHTS study (EY10461)	\$27,000	PI	1993
NEI 20% (grant[suppl] R01 Ey07642-04S1)	\$61,000	(direct)	1991-1993
Allergan Inc. Responses to Glaucoma Meds. in Black Patients	\$20,000	PI	1990-1992
Bausch & Lomb. Metapranolol for Glaucoma	\$24,000	PI	1986-1988
Johnson & Johnson: Thymoxamine in Pigmented Eyes	\$36,000	PI	1987
Glaucoma Research Foundation: Filtering Seton Implants	\$200,000	Co-PI	1984-1987
Allergan. Flubuprofen in Laser Trabeculoplasty (investigator)	\$3,000		1982-1984
UCSF Academic Senate Fellowship	\$19,000		1979-1981

BIBLIOGRAPHY

ARTICLES

1. Schatz H, Drake MV: Self-injected retinal emboli. *Ophthalmology* 86:468-483, 1979.
2. Drake MV, O'Donnell JJ, Sandman RP: Analysis of commercial pilocarpine preparations with HPLC. *J Pharm Sci* 71:358, 1982.
3. O'Donnell JJ, Sandman RP, Drake MV: Measurement of pilocarpine and its degradation products by high-performance liquid chromatography. *J Pharm Sci* 69:1097, 1980.
4. Drake MV: Complications of argon laser trabeculoplasty. *Trans Pac Coast Oto-Ophthalmol Soc* 64:71, 1983.
5. Weinreb RN, Drake MV: Treatment parameters with argon laser trabeculoplasty. *Trans Pac Coast Oto-Ophthalmol Soc* 64:75, 1983.
6. Weinreb RN, Robin AL, Baerveldt G., Drake MV, Blumenthal M, Wilensky J: Fluorobiprofen pretreatment in argon laser trabeculoplasty for primary open-angle glaucoma. *Arch Ophthalmol* 102:11, 1984.
7. Drake MV, O'Donnell JJ, Polansky J: Muscarinic binding affinity of isopilocarpine. *J Pharm Sci* 75(3):278, 1986.
8. Drake MV: The intraocular pressure response to Neodymium YAG laser capsulotomy: Aphakic vs. pseudophakic eyes. *Ophthal Laser Surg* 2(1):19-22, 1987.
9. Drake MV: Neodymium:YAG laser iridotomy. *Surv Ophthalmol* 32:171, 1987.
10. Hoskins HD, Magee SD, Drake MV, Kidd MN: Confidence intervals for change in automated visual fields. *Br J Ophthalmol* 72(8): 591-597, 1988.
11. Drake MV (Ed): Glaucoma Update, *International Ophthalmology Clinics*, vol 30, no 3, p 193, 1990.
12. Drake MV: Glaucomatous visual loss: Fields, color, contrast. *Int Ophthalmol Clin* 30:193, 1990.
13. Hoskins HD, Iwach A, Drake MV: Subconjunctival THC:YAG laser sclerostomy ab externo in the rabbit. *Ophthalmic Surg* 21:589, 1990.
14. Wright MM, Skuta GL, Drake MV et al: Time course of thymoxamine reversal of phenylephrine mydriasis. *Arch Ophthalmol* 108:1729, 1990.
15. Iwach AG, Drake MV, Hoskins HD, Schuster Bl, Vassiliadis A, Crawford JB, Hennings D: A new contact Holmium:YAG laser for cyclophotocoagulation. *Ophthalmic Surg* 22:345, 1991.

16. Hoskins HD, Iwach AG, Vassiliades A, Drake MV, Hennings MS: Subconjunctival THC:YAG laser thermal sclerostomy. *Ophthalmology* 98:1394-1400, 1991.
17. Wilson MR, Drake MV: Glaucoma in Blacks: Epidemiology and management. *Clinical Signs in Ophthalmology*, Vol XIII No. 2:2-16, 1992.
18. Drake MV: Complications of Glaucoma Filtration Surgery. *International Ophthalmology Clinics* 1992 Fall, 31(4):115-130.
19. Drake MV, Iwach A, Hoskins HD: Holmium laser sclerostomy. *Exp Eye Res* 55:27 (Suppl), 1992.
20. Hoskins DH, Drake MV, Minckler DH: Filtering seton implant surgery for glaucoma: An animal trial. *Ophthalmic Surg* 23:702-708, 1992.
21. Iwach AG, Hoskins HD, Drake MV et al: Subconjunctival THC:YAG (Holmium) laser thermal sclerostomy ab externo. *Ophthalmology* 100:356-366, 1993.
22. Drake MV, Wilson MR: Levobunolol compared to dipivifrin b.i.d. in treatment of African American patients with open angle glaucoma. *J Ocular Pharmacol* 9:91-95, 1993.
23. Iwach AG, Hoskins HD, Drake MV, Dickens CJ. Update of the subconjunctival THC:YAG (holmium) laser sclerostomy ab externo clinical trial: 30-month report. *Ophthalmic Surg* 1994; 25:13-21
24. Komaromy, M; Grumbach, K; Drake, M; Vranizan, K; Lurie, N; Keane, D; Bindman, AB. The role of black and Hispanic physicians in providing health care for underserved populations [see comments]. *New England Journal of Medicine*, 1996 May 16, 334(20):1305-10
25. Drake, MV. New medical therapies for glaucoma. *International Ophthalmology Clinics*, 1996 Spring, 36(2):53-60.
26. Iwach, AG; Hoskins, HD Jr; Mora, JS; Dickens, CJ; Drake, MV; Gaffney, MM; Nguyen, N; Wong, PC; Tran, H; Ma, AS. Update on the subconjunctival THC:YAG (holmium) laser sclerostomy Ab externo clinical trial: a 4-year report. *Ophthalmic Surgery and Lasers*, 1996 Oct, 27(10):823-31
27. Drake, MV; Lowenstein, DH. The role of diversity in the health care needs of California. *Western Journal of Medicine*, 1998 May, 168(5):348-54.
28. Dorr, D, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Graphically conquering the SF-36: A tool for illustrating subscale by group over time using SAS/GRAPH(r) Software. *Proceedings of the twenty-third SAS Users Group International Conference*: 856-859, 1998.
29. Gordon, MO., and the Ocular Hypertension Treatment Study (OHTS) Group: The Ocular Hypertension Treatment Study, Design and Baseline Description of the Participants. *Archives of Ophthalmology*, Volume 117, 1999 May, 573-583.
30. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MA for the Ocular Hypertension Study Group. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). *Arch Ophthalmol* 118:1187-1194, 2000

31. Piltz J, Gross, R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO and the OHTS Study Group. Contralateral effect of topical β -adrenergic antagonists in initial one-eyed trials in the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 130:441-453, 2000
32. Brandt JD, Beiser JA, Gordon MO, Kass MA and the OHTS Group. Central Corneal thickness in the Ocular Hypertension Treatment Study (OHTS). *Ophthalmology* 108:1779-1788, 2001
33. Feuer WJ, Parrish RK, II, Schiffman JC, Anderson DR, Budenz DL, Wells MC, Hess, DJ, Kass MA, Gordon MO, and the OHTS Group. The Ocular Hypertension Treatment Study: Reproducibility of cup/disc ratio measurements over time at an Optic Disc Reading Center. *Am J Ophthalmol* 122:19-28, 2002
34. Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E, and the Ocular Hypertension Treatment Study (OHTS). Baseline visual field characteristics in the Ocular Hypertension Treatment Study. *Ophthalmology* 109:432-437, 2002
35. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish, RK, Wilson MR, Gordon MO for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma. *Arch Ophthalmol* 120:701-713, 2002
36. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open angle glaucoma. *Arch Ophthalmol* 120:714-720, 2002
37. Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Dass MA, Gordon MO for the Ocular Hypertension Treatment Study Group. Classification of visual field abnormalities in the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 2003; 121:643-650
38. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Coleman AL, Piltz-Seymour JR, Liebmann JM, Cioffi GA, Trick G, Brandt JD, Gordon MO, Kass MA for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Racial differences in optic disc topography: Baseline results from the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 2004; 122:22-28.
39. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD, Trick G, Cioffi GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kass MA for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study: Study design and baseline factors. *Am J Ophthalmol* 2004; 137:219-227.
40. Higginbotham EJ; Gordon MO; Beiser JA; Drake MV; Bennett GR; Wilson MR; Kass MA; for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals *Arch Ophthalmol*, Jun 2004; 122: 813-820.
41. Coleman AL, Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study (OHTS) Group. Baseline risk factors for the development of POAG in the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 2004; 138(4):684-5.

42. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness and measured IOP response to topical ocular hypotensive medication. *Am J Ophthalmol* 2004; 138:717-722
43. Hernández MT, Lemp GF, Castañeda X, Sanchez M, Aoki B, Tapia-Conyer R, Drake MV. HIV/AIDS Among Mexican Migrants and Recent Immigrants in California and México, *JAIDS*, Vol. 37, Supp. 4, S203, November 2004
44. Kass MA, Gordon MO, Kymes SM for the Ocular Hypertension Treatment Study (OHTS) Group. Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. Letter to Editor. *Arch Ophthalmol* 2005;123:1021-22. PMID:16009857.
45. Keltner JL, Johnson CA, Levine RA, Fan JJ, Cello KE, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group (OHTS). Normal visual field test results following glaucomatous visual field endpoints in the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 2005;123:1201-06. PMID:1828122.
46. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study Group. Baseline topographic optic disc measurements are associated with the development of primary open angle glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 2005;123:1188-97. PMID:16157798.
47. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C, Vandenbroucke R, Kass MA, Gordon MO, the Ocular Hypertension Treatment Group: Test-retest Reproducibility of Optic Disk Deterioration Detected From Stereophotographs by Masked Graders. *Am J Ophthalmol* 2005;140:762-64. PMID:16226544.
48. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group. Management of ocular hypertension: A cost-effectiveness approach from the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 2006;141:997-1008. PMID:1775049.
49. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Asymmetries and visual field summaries as predictors of glaucoma in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 2006;47:3896-3903. PMID:1995656.
50. Keltner JL, Johnson CA, Anderson DR, Levine RA, Fan JJ, Cello KE, Quigley HA, Budenz DL, Parrish II RK, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group. The Association between Glaucomatous Visual Fields and Optic Nerve Head Features in the OHTS. *Ophthalmology* 2006;113:1603-12. PMID:16949445.
51. Herman DC, Gordon MO, Beiser JA, Chylack Jr. LT, Lamping KA, Schein OD, Soltau JB, Kass MA. Topical ocular hypotensive medication and lens opacification: Evidence from the Ocular Hypertension Treatment Study (OHTS). *Am J Ophthalmol* 2006;142:800-12. PMID:1976472.
52. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish II RK, Piltz-Seymour JR, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. *Ophthalmology* 2006;113:2137-43. PMID:1995568.

53. The Ocular Hypertension Treatment Study (OHTS) Group and the European Glaucoma Prevention Study (EGPS) Group. A validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. *Ophthalmology* 2007;114:10-19. PMID:1995665.
54. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Comparison of initial intraocular pressure response to topical beta-adrenergic antagonists and prostaglandin analogues in African Americans and whites in the Ocular Hypertension Treatment Study (OHTS). *Arch Ophthalmol* 2007;125:454-9. PMID:17420364
55. Keltner JL, Johnson CA, Cello KE, Bandermann SE, Fan JJ, Levine RA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). *J Glaucoma*. *J Glaucoma* 2007;16:665-9. PMID:18091452
56. Hernández MT, Lemp GF, Castañeda X, Sanchez M, Aoki B, Hanson J, Magis-Rodriguez C, Drake MV. The Effect of Migration on HIV High-Risk Behaviors among Mexican Migrants, *JAIDS*, November 2007
57. Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group. Is a history of diabetes mellitus protective against developing primary open-angle glaucoma? *Arch Ophthalmol* 2008;126:280-1. PMID:18268230
58. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA and the Ocular Hypertension Treatment Study Group. Changes in central corneal thickness over time: the Ocular Hypertension Treatment Study. *Ophthalmology*. 2008;115:1550-1556. PMID:18378313.
59. Bhorade AM, Gordon MO, Wilson B, Weinrab RN, Kass MA and the Ocular Hypertension Treatment Study Group. Variability of intraocular pressure measurements in observation participants in the Ocular Hypertension Treatment Study. *Ophthalmology*. 2009;116:717-724 NIHMS ID:159280.
60. Drake, MV. The Need for Diversity in Medical Education, *Arch Ophthalmol*, Oct 2009; 127(10):1387-1388.

MONOGRAPHS

1. Blue Ridge Academic Health Group, *Advancing Value in Healthcare: The Emerging Transformational Role of Informatics*, 2008.
2. Blue Ridge Academic Health Group, *Fall 2008 Policy Proposal: A United States Health Board*, 2008.
3. Blue Ridge Academic Health Group, *The Role of Academic Health Centers in Addressing the Social Determinants of Health*, 2010.

BOOKS

1. Lieberman M, Drake MV: *A Simplified Guide to Computerized Perimetry*, Slack, Thorofare NJ, 1987. Spanish Language: 1992 Italian: 1993
2. Harrington DO, Drake MV: *The Visual Fields, A Textbook and Atlas of Clinical Perimetry*, VI Ed, CV Mosby, St Louis, 1990. Spanish Language: 1994
3. Lieberman M, Drake MV: *Computerized Perimetry, a Simplified Guide*. 2nd ed, Slack, Thorofare NJ, 1993.
4. Stamper R, Lieberman, M and Drake MV: *Becker/Shaffer's Diagnosis and Treatment of the Glaucomas* 7th Edition CV Mosby, 1999

5. (Committee Author) Smedley BD, Butler AS, Bristow LR, ed. In the Nation's Compelling Interest: ensuring diversity in the health care workforce/Committee on Institutional and Policy-Level Strategies for Increasing the Diversity of the US Health Care Workforce, Board on Health Sciences Policy; Institute of Medicine of the National Academies, 2004
6. Stamper R, Lieberman, M and Drake MV: Becker/Shaffer's Diagnosis and Therapy of the Glaucomas, 8th Edition, CV Mosby, 2009

BOOK CHAPTERS

1. Drake MV: Approach to Ocular Emergencies. In: Callaham M (Ed) Current Therapy in Emergency Medicine. BC Decker Inc 1987.
2. Drake MV: Approach to Ocular Emergencies. In: Callaham M (Ed) Current Therapy in Emergency Medicine. BC Decker Inc 1987.
3. Drake MV: Visual Field Testing of Patients with Advanced Glaucoma. In: E Higginbotham, D Lee (Eds); Management of Difficult Glaucoma, WB Saunders 1994.
4. Drake, MV: Glaucoma. In: Rakel, RE ed; Conn's Current Therapy, WB Saunders, Philadelphia. 1997, p. 957-960.
5. Drake MV: The Glaucomatous Field. In: DM Albert, FA Jakobiec (Eds): Principles & Practice of Ophthalmology. Chap 113. WB Saunders 1994, Second Edition: Chap 193. 1999
6. Drake MV: Field Loss in Glucoma In: Clinical Management of Glaucoma, Higginbotham E, Lee D (Eds). 2003

ABSTRACTS

1. Kramer SG, Oyakowa R, Drake MV: Prostaglandins and the pupil. Invest Ophthalmol & Vis Res (ARVO Suppl), April 1976.
2. Drake MV, O'Donnell JJ, Sandman RP: HPLC analysis of isopilocarpine in commercial pilocarpine. Invest Ophthalmol & Vis Res (ARVO Suppl), April 1980, p 68.
3. Drake MV, O'Donnell JJ, Sipila I, Hopkins S: Ornithineaminotransferase activity in eye and skeletal muscle: Hormonal regulation. Invest Ophthalmol (Suppl) 20:211, 1981.
4. Zlock D, Zumburum A, Alvarado J, Drake MV, Polansky J: Cholinergic receptor and acetyl cholinesterase in ciliary muscle. Invest Ophthalmol & Vis Sci (ARVO Suppl) 22, 1982.
5. Zlock D, Zumburum A, Alvarado J, Drake MV, Polansky J: Cholinergic receptor and acetyl cholinesterase in ciliary muscle. Invest Ophthalmol & Vis Sci (ARVO Suppl) 22, 1982.
6. Drake MV: Peripheral static testing in early glaucoma. Ophthalmology (Suppl) 94(9), 1987.
7. Drake MV, Wright MM, Skuta GL, Chang LF, Rabbani R, Teikari J, March DD: Thymoxamine reverses phenylephrine induced mydriasis. Invest Ophthalmol & Vis Sci (Suppl) 30(3), 1989.
8. Iwach A, Drake MV, Hoskins HD. Ab externo holmium YAG laser sclerostomy in rabbits. ARVO (Suppl) 31(3), 1990.

9. Hoskins HD, Drake MV, Iwach A; Transscleral cyclophotocoagulation using the holmium YAG laser. *ARVO (Suppl)* 31(3), 1990.
10. Drake MV, Bosetti JB, Jameson N, Stern WH: Fibrin thrombin tissue adhesive for healing experimental corneal perforations. *ARVO (Suppl)* 31(3), 1990.
11. Hoskins HD, Iwach A, Vissiliadis A, Drake MV: Subconjunctival THC:YAG (Holmium) laser thermal sclerostomy. *Ophthalmology (Suppl)* 97(9):126, 1990.
12. Iwach AG, Drake MV, Hoskins HD et al: THC:YAG (Holmium) laser thermal sclerostomy ab externo. *Invest Ophthalmol & Vis Sci* 33(4)(Suppl):1018, 1992.
13. Iwach AG, Drake MV, Hoskins HD et al: THC:YAG (Holmium) laser thermal sclerostomy ab externo. *Invest Ophthalmol & Vis Sci* 33(4)(Suppl):1018, 1992.
14. Royal G, Drake MV, Alvarado J et al: One year follow-up of Nd:YAG contact transscleral laser cyclophotocoagulation. *Invest Ophthalmol & Vis Sci* 33(4):1268.
15. Drake MV, Seiff S, Horton JR: Bilateral visual field improvement with unilateral optic nerve sheath fenestration. *Documenta Ophthalmologica (abst) Proc Xth International Perimetric Society*, 1992.
16. Drake MV, Huang AS: The Tubingen electronic campimeter snowfield program for glaucoma screening. *Documenta Ophthalmologica (abst) Proc Xth International Perimetric Society*, 1992.
17. Huang AS, Lieberman MF, Drake MV, Alvarado JA: Three-year follow up of Nd:YAG contact transscleral laser cytophotocoagulation. *Invest Ophthalmol & Vis Sci (Suppl)* March 1994.
18. Wong, KF, Achtenberg, JF, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Automated Forms of Processing: Trials, Tribulations and Triumphs. *Controlled Clinical Trials* 15:3S, p. 76S, 1994.
19. Gordon MO, Li Z, Schechtman KB, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group: Minimizing Variability and Regression to the Mean in IOP Measurements. *Invest Ophthalmol Vis. Sci* 36:4, S81, 1995.
20. Drake MV. Managing Low (Normal) Tension Glaucoma. *J Natl Med Assn Suppl.* 26-27; July 1995
21. Drake MV. Affirmative Action and University of California Med School Admission. *Acad. Med. Suppl* (In Press)
22. Wong, KF, Gordon, MO, Achtenberg, JF, and the Ocular Hypertension Treatment Study (OHTS) Group: Electronic Document Archival for a Data Coordinating Center. *Controlled Clinical Trials* 16:3S, p. 38S, 1995.
23. Drake, MV: Normal Tension Glaucoma. *Abstract Book National Medical Association Scientific Assembly*, p. 27, 1995.
24. Gordon MO, Schechtman KB, Li Z, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group: A Protocol to Minimize Bias and Regression to the Mean in Measurement of Intraocular Pressure. *Controlled Clinical Trials* 16:3S, p. 98S, 1995

25. Gordon, MO, Johnson, CA, Spurr, JO, Kass, MA, and the Ocular Hypertension Treatment Study (OHTS) Group: Pluses and Minuses of Relaxing Fixation Loss Criterion. *Invest Ophthalmol Vis. Sci* 37:3, p.S507, 1996.
26. Wong, K, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: An inexpensive electronic system for handling adverse event reports. *Controlled Clin Trial* 17:2S, 1996.
27. Wong, K, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Automatic forms processing with Windows 95: Hyperbole? *Controlled Clin Trial* 17:2S, 1996.
28. Kahn, JG; Drake, M; Washington, E. Cost-effectiveness of primary care-based glaucoma screening of African Americans. *Abstr Book Assoc Health Serv Res*, 1997, 14:250-1.
29. Wong, K, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Electronic systems for handling adverse event reports. *Controlled Clinical Trial* 18(3S):145S, 1997.
30. Bennett, GR, Cioffi, GA, Dorr, D, Gordon, MO, Beck, A, Fechtner, R, Kass, M, and the Ocular Hypertension Treatment Study (OHTS) Group: Racial differences in response to glaucoma medications in ocular hypertensive patients. *Invest Ophthalmol Vis. Sci* 38(3):S278, 1997.
31. Gross, R, Piltz, J, Shin, DH, Kass, MA, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Contralateral effect of topical beta-blockers on intraocular pressure in the Ocular Hypertension Treatment Study. *Invest Ophthalmol Vis. Sci* 38(4):S1056, 1997.
32. Dorr D, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Graphically conquering the SF-36: A tool for illustrating subscale by group over time using SAS/GRAPH(r) Software. *Proceedings of the twenty-third Annual SAS Users Group International Conference*: 856-859, 1998
33. Keltner, JL, Johnson, CA, Spurr, JO, Kass, MD, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 39(4):S493, 1998.
34. Gordon, MD, Kass, MA, Heuer, D, Higginbotham, E, Parrish, R, and the Ocular Hypertension Treatment Study (OHTS) Group: Baseline demographics and clinical characteristics of patients enrolled in the Ocular Hypertension Treatment Study. *Invest Ophthalmol Vis Sci* 39(4):S878, 1998.
35. Morris, PA, Wilder, AKA, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Site visit strategies to increase collaboration of the clinic, resource centers and coordinating center. *Controlled Clinical Trials* 19(3S):51S, 1998.
36. Dorr, DA, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: A simple graphical method for displaying multiple dimensions by group over time: and example using the SF- *Controlled Clin Trials* 19(3S)72S, 1998/
37. Fischbach E, Achtenberg J, Clark K, Tourville D, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: (Under) Estimating paper storage requirements for a multicenter clinical trial. *Controlled Clin Trials* 19(3S):84S, 1998.

38. Bednarski M, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS) and the Collaborative Longitudinal Evaluation of Keratoconus Study (CLEK) Groups: A quick and dirty method for delivering SAS(r) reports via the world wide web. MWSUG Conference Proceedings, 405
39. Bednarski MA, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS) Group: Delivering coordinating center reports to clinics via the world wide web. *Controlled Clin Trials* 20(2S):60S, 1999.
40. Wilder AK, Morris PA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Offering continuation education credits at clinic coordinating meeting. *Controlled Clin Trials* 20(2S):67S, 1999.
41. Morris PA, Wilder AK, Bednarski MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Accessing SAS reports by the central coordinators via the world wide web. *Controlled Clin Trials* 20(2S):68S, 1999.
42. Feuer WJ, Parrish RK, Wells MC, Schiffman JC, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Reproducibility of reading of optic disc cup/disc ratio in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 40(4):S283, 1999.
43. Keltner JL, Johnson CA, Spurr JO, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Classification of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 40(4):S69, 1999.
44. Goldstone R, Drake MV: Women of Color and the Medical School Experience. In press, *Academic Medicine* 2000
45. Goldstone R, Adams M, and Drake MV: Orienting Medical Students to Diversity. In press, *Academic Medicine* 2000
46. Keltner J, Johnson C, Cello K, and the Ocular Hypertension Treatment Study (OHTS) Group: Severity of the Types of Visual Field Abnormalities in the Ocular Hypertension Treatment Study. AVRO, NANOS 2000.
47. Long E, Dunn D, Gordon M, and the Ocular Hypertension Treatment Study (OHTS) group: A Publications and Presentation Policy for a Multicenter Clinical Trial. SCT 2000.
48. Randant D, Long E, Gordon M, the Ocular Hypertension Treatment Study (OHTS) Group. Handling forms in a multicenter clinical trial. *Control Clin Trials* 21(2S): 100S, 2000.
49. Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, Bander mann SE, Edwards MA, Ocular Hypertension Study Group. Visual field technician performance in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 42(4): S152, 2001.
50. Brandt JD, Beiser J, Kass MA, Gordon MO, for the OHTS Study Group. The relationship of corneal thickness and IOP response to topical β -blocker in the Ocular Hypertension Treatment Study. *Invest Ophthalmol Vis Sci* 42(4): S421.
51. Wilder AK, Morris PA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Improving timeliness of annual IRB approvals. *Control Clin Trials* 22(2S): 79S, 2001.

52. Bednarski MA, Beiser JA, Gordon MA, Morris PA, Wilder AK, and the Ocular Hypertension Study (OHTS) Group. Providing performance reports to clinics via the world wide web. *Control Clin Trials* 22(2S): 80S, 2001.
53. Morris PA, Wilder AK, Bednarski M, Gordon MO, and the Ocular Hypertension Treatment Study Group. Omnibus clinic tracking report. *Control Clin Trials* 22(2S): 83S, 2001.
54. Bednarski MA, Clark KA, Hornbeck EM, Gordon MO. Dynamic data retrieval using SAS/IntrNet. SAS Users Group International, paper 197, April 14
55. Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the Ocular Hypertension Study Group. Viewing case report forms on the web without scanning data. *Control Clin Trials* 23 (2S):40S, 2002.
56. Heuer DK, Higginbotham EJ, Kass MA, Parrish RK, Beiser JA, Gordon MO and the Ocular Hypertension Treatment Study Group. Is there a penalty for delayed treatment in ocular hypertensives? Evidence from the Ocular Hypertension Treatment Study (OHTS). Presented at ARVO, May 4-9, 2003.
57. Achtenberg JF, Hornbeck EM, Gordon MO, and the Ocular Hypertension Treatment Study Group. Enhanced documentation of case report forms. *Control Clin Trials* 24(3S):180S, 2003.
58. Bednarski MA, Achtenberg JF, Gordon MO, and the Ocular Hypertension Treatment Study Group. Tracking and reporting multi-stage processes in a clinical trial. *Control Clin Trials* 24(S): 187S, 2003.
59. Kymes SM, Gordon MO, and the Ocular Hypertension Treatment Study Group. Economic evaluation in randomized clinical trials - a promise half met? *Control Clin Trials* 24(3S): 187S, 2003.
60. Morris PA, Wilder AK, Gordon MO, and the Ocular Hypertension Treatment Study Group. Encouraging participation after protocol change. *Control Clin Trials* 24(S)214S, 2003.
61. Keltner JL, Johnson CA, Fan J, Cello KE, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS). Types of visual field abnormalities that subsequently become visual field primary open-angle glaucoma in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 45:E-Abstract 2134. Presented at ARVO, April 25-30, 2004.
62. Coleman AL, Gordon MO, Beiser JA, Kass MA and the Ocular Hypertension Treatment Study. A predictive model for the development of POAG in the Ocular Hypertension Treatment Study excluding pattern standard deviation(PSD) and vertical cup/disc ratio (VC/D). *Invest Ophthalmol Vis Sci* 45:E-Abstract 955. Presented at ARVO, April 25-30, 2004.
63. Budenz DL, Beiser JA, Piltz JR, Parrish RK, Anderson DR, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study Group. Detection and predictive value of optic disc hemorrhages in the Ocular Hypertension Treatment Study. *Invest Ophthalmol Vis Sci* 45:E-Abstract 940. Presented at ARVO, April 25-30, 2004.
64. Beiser JA, Hornbeck E, Morrison D, Gordon MO, Goldberg J. De-identification of shared datasets. *Clinical Trials* 2004;1(1S):274.
65. Mansberger SL, Hughes BA, Gordon MO, Spaner SL, Beiser, JA, Cioffi GA, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Comparison of IOP response to topical beta-adrenergic antagonists and prostaglandin analogues in African Americans and whites: The Ocular

- Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2005;46: E-Abstract 2449. Presented at ARVO.
66. Keltner JL, Johnson CA, Cello KE, Fan J, Bandermann SE, Kass MA, Gordon MO, Beck RW and the Ocular Hypertension Treatment Study (OHTS) group. Visual field quality control in the Ocular Hypertension Treatment Study and in the 10-Year Optic Neuritis Treatment Trial (ONTT) Follow-Up Study. Invest Ophthalmol Vis Sci 2005;46: E-Abstract 3738. Presented at ARVO.
 67. Kass MA, Beiser JA, Herman D, Lamping K, Soltau J, Gordon MO and the Ocular Hypertension Treatment Study Group. Is there an association of topical ocular hypotensive medication with lens opacification and visual function?: Evidence from the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2005; 46: E-Abstract 2448. Presented at ARVO.
 68. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Alborno MC, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Test-retest reproducibility of determining optic disc deterioration in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2005;46: E-Abstract 3630. Presented at ARVO.
 69. Zangwill LM, Weinreb RN, Beiser JA, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Kass MA, Gordon MO and the OHTS CSLO Ancillary Study Group. Baseline topographic optic disc measurements are associated with the development of primary open angle glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the OHTS. Invest Ophthalmol Vis Sci 46: E-Abstract 3631. Presented at ARVO May 1-6, 2005.
 70. Keltner JL, Johnson CA, Cello KE, Fan J, Levine RA, Bandermann SE, Kass MA, Gordon MO, Beck RW and the Ocular Hypertension Treatment Study Group. Visual Field Quality Control in the Ocular Hypertension Treatment Study (OHTS) and the Optic Neuritis Treatment Trial (ONTT). Invest Ophthalmol Vis Sci 2006; E-Abstract 3394. Presented at ARVO.
 71. Brandt JD, Beiser JA, Gordon MO, Lin SC, Alexander MY, Kass MA and the Ocular Hypertension Treatment Study Group. Time Dependent Changes in Central Corneal Thickness in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2006; E-Abstract 4422. Presented at ARVO.
 72. Morris PA, Roediger T, Achtenberg J, Bednarski M, Clark K, Hornbeck B, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Certification, training, and support of a web-based data entry system. Clinical Trials 2006; 3:191-247. Presented at SCT.
 73. Clark KA, Bednarski MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS). Integrating adverse event data into a web-based data management. Clinical Trials 2006; 3:191-247. Presented at SCT.
 74. Bandermann SE, Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, and Ocular Hypertension Treatment Study Group. A Comparison Of Full Threshold and Swedish Interactive Threshold Algorithms (SITA) Testing procedures in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2007;E-Abstract 1643. Presented at ARVO.
 75. Artes PH, Chauhan BC, Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, and Ocular Hypertension Treatment Study Group. Longitudinal and Cross-Sectional Analyses of Visual Field

- Progression in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2007;E-Abstract 4447. Presented at ARVO.
76. Bhorade AM, Wilson BS, Palmberg P, Miller E, Chang RT, Kass MA, Gordon MO, and Ocular Hypertension Treatment Study Group. The Predictive Accuracy of the One-Eyed Trial in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2007; E-Abstract 5555. Presented at ARVO.
 77. Achtenberg JF, Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the Ocular Hypertension Treatment Study Group. Phased transition from traditional data entry to a web-based system. Presented at SCT May 21-24, 2007.
 78. Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Is a history of diabetes mellitus (DM) protective against developing primary open-angle glaucoma (POAG)? Presented at the American Glaucoma Society, March 7, 2008.
 79. Keltner JL, Johnson CA, Cello KE, Brusini P, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Application of Brusini's Glaucoma Staging System 2 (GSS 2) to glaucomatous visual fields in the Ocular Hypertension Treatment Study. Presented at ARVO, April 27, 2008.
 80. Bhorade AM, Wilson BS, Palmberg P, Miller E, Weinreb R, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Intraocular pressure variability in observation participants in the Ocular Hypertension Treatment Study. Presented at ARVO, April 28, 2008.
 81. Kymes SM, Kass MA, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study Group. The 20-year incidence of primary open-angle glaucoma among people with ocular hypertension – A decision analytic approach. Presented at ARVO, May 1, 2008.
 82. Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Retinal vein occlusions (RVO) in the Ocular Hypertension Treatment Study. Presented at ARVO, May 1, 2008.
 83. Long EF, Dunn D, Gordon MO, the Ocular Hypertension Treatment Study group. Close-out manual of procedures for a long-term clinical trial. Presented at the Society for Clinical Trials. May 19, 2008.
 84. Gordon MO, Sarli C, Long EF, LaRue C, the Ocular Hypertension Treatment Study Group. Assessing the impact of research. Presented at the Society for Clinical Trials, May 20, 2008.

MAJOR PUBLICATIONS OF THE UC OFFICE OF HEALTH AFFAIRS

1. *Special Report on Medical Student Diversity*, Prepared for the President of the University of California by the Medical Student Diversity Task Force, November 2000
2. CHBRP Report 1, 2004
3. CHBRP Report 2, 2005
4. *Development of Standards for use of Non-Transplant Human Anatomical Materials*, prepared under the direction of the Office of Health Affairs by Navigant Consulting, Inc. December 2004
5. *Health Sciences Education: Workforce Needs and Enrollment Planning*, Universitywide Health Sciences Committee, subcommittee of the Academic Planning Council, April 2005

OTHER

1. Drake MV: Treatment Parameters for Automated Perimeters. Audio Digest 23:4, 1985.
2. Drake MV: Laser Therapy and Glaucoma. Audio Journal Review 2:8, 1986.
3. Do, D and Drake MV: Detecting Glaucoma: How to Catch the Silent Thief of Sight. UCSF J of Medical Student Research. Spring, 1997